Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed security
Listed on NASDAQ
DE headquartered
Headquartered in Germany

BioNTech SE - ADR

$110.40
BNTX
Jan 25, 3:53:00 PM GMT-5 · USD · NASDAQ · Disclaimer

In the news

Financial performance
(EUR)Q3 2020Year/year change
Revenue
67.46M135.36%
Net income
-210.03M-597.71%
Diluted EPS--
Net profit margin-311.35%-196.44%
Operating income-193.34M-424.41%
Net change in cash417.45M133.97%
Cash on hand990.46M113.78%
Cost of revenue6.84M61.70%
About
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020 BioNTech developed, in conjunction with Pfizer, the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK. It was the first mRNA vaccine ever authorized. Some days later the vaccine got also an emergency approval in the United States, Canada, and Switzerland. Wikipedia
Founded
2008
Headquarters
Employees
1,800

Key stats

Previous close
The last closing price
$108.44
Day range
The difference between the high and low prices over the past day
$105.14 - $110.98
Year range
The difference between the high and low prices over the past 52 weeks
$28.00 - $131.00
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
26.42B USD
Volume
The average number of shares traded each day over the past 30 days
3.55M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
Primary exchange
Listed exchange for this security
NASDAQ
About
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020 BioNTech developed, in conjunction with Pfizer, the RNA vaccine BNT162b2 for preventing COVID-19 infections, which offers a 95% efficacy. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK. It was the first mRNA vaccine ever authorized. Some days later the vaccine got also an emergency approval in the United States, Canada, and Switzerland. Wikipedia
Founded
2008
Headquarters
Employees
1,800

Discover more

You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more

People also search for

Search
Clear search
Close search
Google apps
Main menu